| Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Clonal dynamics of aplastic anemia/paroxysmal nocturnal hemoglobinuria |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag |
|
The New England Journal of Medicine |
Aplastic Anemia |
| Clonal Dynamics of Hematopoiesis in Aplastic Anemia after Immunosuppression and Eltrombopag |
|
NEJM Evid |
Aplastic Anemia |
| Clonal evolution in aplastic anemia: failed tumor surveillance or maladaptive recovery? |
|
Leukemia & Lymphoma |
Aplastic Anemia |
| Clonal Hematopoiesis and therapy related MDS/AML |
|
Best Practice & Research. Clinical Heamatology |
Myelodysplastic Syndromes (MDS) |
| Clonal Hematopoiesis Diversity in Aplastic Anemia - When Does It Matter Clinically? |
|
The New England Journal of Medicine |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy |
|
Annual Review of Pathology: Mechanisms of Disease |
Aplastic Anemia, Myelodysplastic Syndromes (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia |
|
The New England Journal of Medicine |
Aplastic Anemia |
| Clonal Selection and Evolution after Treatment of Severe Aplastic Anemia |
|
NEJM Evid |
Aplastic Anemia |
